Applied DNA Sciences Files Amendment to Annual Report

TL;DR

<b>Applied DNA Sciences, Inc. has filed an amendment to its 2023 annual report, confirming its listing on Nasdaq under APDN.</b>

AI Summary

APPLIED DNA SCIENCES INC (BNBX) filed a Amended Annual Report (10-K/A) with the SEC on January 26, 2024. This filing is an amendment (No. 1) to the annual report on Form 10-K for the fiscal year ended September 30, 2023. The company's common stock is registered and traded on The Nasdaq Stock Market LLC under the trading symbol APDN. Applied DNA Sciences, Inc. is incorporated in Delaware with its principal executive offices located at 50 Health Sciences Drive, Stony Brook, New York. The filing indicates that the company has filed all required reports for the preceding 12 months and has been subject to such filing requirements for the past 90 days. The company was formerly known as PROHEALTH MEDICAL TECHNOLOGIES INC, DCC ACQUISITION CORP, and DATALINK CAPITAL CORP/TX/.

Why It Matters

For investors and stakeholders tracking APPLIED DNA SCIENCES INC, this filing contains several important signals. This amendment suggests potential updates or corrections to the original 10-K filing, which could contain material information for investors. As a publicly traded company on Nasdaq, Applied DNA Sciences is subject to ongoing reporting requirements, and this amendment is part of that compliance process.

Risk Assessment

Risk Level: low — APPLIED DNA SCIENCES INC shows low risk based on this filing. The risk is low as this is a routine amendment to an annual report, not indicating new negative developments.

Analyst Insight

Investors should review the specific changes made in Amendment No. 1 to the 10-K filing for any material updates to the company's financial or operational status.

Key Numbers

• 2023-09-30 — Fiscal Year End (Reported Fiscal Year End)
• 2024-01-26 — Filing Date (Date of Filing)
• APDN — Trading Symbol (Common Stock Trading Symbol)
• 001-36745 — Commission File Number (SEC Commission File Number)

Key Players & Entities

• APPLIED DNA SCIENCES INC (company) — Registrant Name
• 001-36745 (regulator) — Commission File Number
• 0000744452 (company) — Central Index Key
• 8734 (company) — Standard Industrial Classification
• 59-2262718 (company) — IRS Number
• 50 Health Sciences Drive (company) — Business Address Street 1
• Stony Brook (company) — Business Address City
• New York (company) — Business Address State

Forward-Looking Statements

• APPLIED DNA SCIENCES INC will continue to maintain its listing on The Nasdaq Stock Market LLC. (APPLIED DNA SCIENCES INC) — high confidence, target: 2025-01-26

FAQ

Industry Context

Applied DNA Sciences operates in the testing laboratories sector, providing services that likely involve DNA analysis and related technologies.

Regulatory Implications

As a publicly traded company, Applied DNA Sciences is subject to the reporting requirements of the Securities Exchange Act of 1934, including filing annual reports (10-K) and amendments.

What Investors Should Do

1. Review Amendment No. 1 to the 10-K for specific changes and disclosures.
2. Monitor future SEC filings from Applied DNA Sciences for ongoing operational and financial updates.
3. Analyze the company's business segments and financial performance in the full 10-K report once available.

Key Dates

• 2023-09-30: Fiscal Year End — The period covered by the annual report.
• 2024-01-26: Filing Date — Date the amendment was filed with the SEC.

Year-Over-Year Comparison

This is an amendment to the previously filed 10-K for the fiscal year ended September 30, 2023. Specific details of changes from the original filing are not provided in this header information.

Key Financial Figures

• $0.001 — ) on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar

Filing Documents

• tm244099d1_10ka.htm (10-K/A) — 463KB
• tm244099d1_ex31-3.htm (EX-31.3) — 4KB
• tm244099d1_ex31-4.htm (EX-31.4) — 4KB
• 0001104659-24-007279.txt (&nbsp;) — 725KB
• apdn-20230930.xsd (EX-101.SCH) — 3KB
• apdn-20230930_lab.xml (EX-101.LAB) — 35KB
• apdn-20230930_pre.xml (EX-101.PRE) — 23KB
• tm244099d1_10ka_htm.xml (XML) — 5KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 10 ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 18 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 20 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 20 PART IV ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES 21 3 Part III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE Board of Directors, Executive Officers and Key Employees The Board of Directors (the "Board of Directors") currently consists of six members. The term of each Director expires at our next annual meeting or until his or her successor is appointed. Our executive officers are elected by, and serve at the discretion of, the Board of Directors. There are no family relationships between any directors or executive officers. The ages of the directors and executive officers are shown as of January 19, 2024. Name Ages Position James A. Hayward 70 Chief Executive Officer, President and Chairman of the Board of Directors Robert B. Catell 87 Director Joseph D. Ceccoli 60 Director Sanford R. Simon 81 Director Yacov A. Shamash 74 Director Elizabeth M. Schmalz Shaheen 72 Director Beth Jantzen 47 Chief Financial Officer Judith Murrah 65 Chief Operating Officer, Chief Information Officer and Secretary Clay Shorrock 40 Chief Legal Officer Set forth below is biographical information with respect to the aforementioned individuals. James A. Hayward, Ph.D. , Sc.D. Dr. James A. Hayward has been our Chief Executive Officer since March 17, 2006, a director on the Board of Directors since September 28, 2005 and our President and the Chairman of the Board of Directors since June 12, 2007. He was previously our acting Chief Executive Officer since October 5, 2005. He also served as Acting Chief Financial Officer from August 20, 2013 through October 13, 2013. Dr. Hayward received his Ph.D. in Molecular Biology from the State University of N

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION Compensation Overview The compensation committee has overall responsibility for approving and evaluating the compensation arrangements for our named executive officers. Our named executive officers for fiscal 2023 are our Chief Executive Officer and President, Dr. James Hayward, our Chief Financial Officer, Beth Jantzen, our Chief Operating Officer and Chief Information Officer, Judith Murrah, and our Chief Legal Officer, Clay Shorrock. Our Chief Executive Officer provides recommendations to the compensation committee with respect to the compensation of the named executive officers other than himself. However, the compensation committee is free to make decisions that are contrary to the Chief Executive Officer's recommendations. Our Executive Compensation Philosophy and Objectives General The fundamental purpose of our executive compensation program is to assist us in achieving our financial and operating performance objectives. Specifically, we attempt to tailor an executive's compensation to (1) retain and motivate the executive, (2) reward him or her upon the achievement of Company-wide and individual performance, and (3) align the executive's interest with the creation of long-term stockholder value, without encouraging excessive risk taking. To that end, and within the context of the stage of our company, we have historically compensated our named executive officers through a mix of base salary, equity-based incentives and cash bonuses. Our business model is based on our ability to establish long-term relationships with clients and to maintain our strong mission, client focus, entrepreneurial sp

View Full Filing

View this 10-K/A filing on SEC EDGAR